Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice
Hepatology Research · 2023-05 · 53 (5) · 460-472
DOI: 10.1111/hepr.13879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 23.01.2023. Verfasst von Yusuke Watanabe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Preemptive Medicine for Digestive Disease and Healthy Active Life, School of Medicine, Niigata University, Niigata, Japan. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Grant-in-Aid for Scientific Research from the Japanese Society for the Promotion of Sciences.
Abstract (Originalsprache)
Aim
Acute‐on‐chronic liver failure (ACLF), a disease with poor prognosis, is reportedly caused by cellular senescence due to mitochondrial dysfunction. In this study, we described and analyzed the underlying mechanism of a novel approach for ACLF using ABT263/navitoclax (Navi) that selectively eliminates senescent cells.
Methods
Irradiation‐induced senescent hepatocytes were used for in vitro evaluation of the effects of Navi on ACLF ( n = 6 for each group). Lipopolysaccharide‐ and carbon tetrachloride‐induced ACLF mouse model was used for in vivo evaluation of the effects of Navi administration compared with the control using one‐way or two‐way analysis of variance, followed by Student's t ‐test or Kruskal–Wallis test. The effects on the senescence‐associated secretory phenotype ( n = 8 for each group) and mitochondrial functions, including adenosine triphosphate concentration and membrane potential ( n = 8 for each group), were investigated using real‐time polymerase chain reaction, immunohistochemistry, and enzyme analysis.
Results
Navi eliminated irradiation‐induced senescent hepatocytes in vitro , leading to non‐senescent hepatocyte proliferation. Navi eliminated senescent cells in the liver in vivo , resulting in downregulation of mRNA expression of senescence‐associated secretory phenotype factors, a decrease of liver enzymes, and upregulated proliferation of non‐senescent cells in the liver. Regarding mitochondrial functional assessment in the liver, adenosine triphosphate concentration and membrane potential were upregulated after Navi administration in vitro and in vivo .
Conclusions
Navi may ameliorate ACLF damage by eliminating senescent cells in the liver, downregulating senescence‐associated secretory phenotype factors, and upregulating mitochondrial functions. We believe that this novel approach using Navi will pave the way for ACLF treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Preemptive Medicine for Digestive Disease and Healthy Active Life, School of Medicine, Niigata University, Niigata, Japan.
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
ORCID-Profile: Yoshihisa Arao, Hiroteru Kamimura
Förderung
- Grant-in-Aid for Scientific Research from the Japanese Society for the Promotion of Sciences
Zitieren
APA
Watanabe, Y., Abe, H., Kimura, N., Arao, Y., Ishikawa, N., Yuichiro, M., Setsu, T., Sakamaki, A., Kamimura, H., Yokoo, T., Kamimura, K., Tsuchiya, A., & Terai, S. (2023). Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice. Hepatology Research, 53(5), 460-472. https://doi.org/10.1111/hepr.13879
Vancouver
Watanabe Y, Abe H, Kimura N, Arao Y, Ishikawa N, Yuichiro M, et al. Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice. Hepatology Research. 2023;53(5):460-472. doi:10.1111/hepr.13879
BibTeX
@article{Watanabe2023,
author = {Watanabe, Yusuke and Abe, Hiroyuki and Kimura, Naruhiro and Arao, Yoshihisa and Ishikawa, Natsuki and Yuichiro, Maeda and Setsu, Toru and Sakamaki, Akira and Kamimura, Hiroteru and Yokoo, Takeshi and Kamimura, Kenya and Tsuchiya, Atsunori and Terai, Shuji},
title = {Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice},
journal = {Hepatology Research},
year = {2023},
volume = {53},
number = {5},
pages = {460--472},
doi = {10.1111/hepr.13879}
}
EUVIMED